SCHEMBL10086148

SCHEMBL10086148

CCOC(=O)c1c(C)[nH]c2ccc(C)cc2c1=O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.63
ALDH1A1 P00352 7/20 0.58
KDM4E B2RXH2 6/20 0.58
MAPT P10636 5/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
RAB9A P51151 3/20 0.58
NPC1 O15118 2/20 0.58
TP53 P04637 1/20 0.58
HSD17B10 Q99714 4/20 0.57
HCRTR1 O43613 1/20 0.53
HPGD P15428 3/20 0.52
LMNA P02545 3/20 0.52
PKM P14618 1/20 0.50
ALOX5 P09917 1/20 0.49
TSHR P16473 1/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
HTT P42858 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18549336 0.88 GAA (0.61) GAAALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL31060356 0.88 GAA (0.61) GAAALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL31080886 0.86 CSF1R (0.61) GAAALDH1A1KDM4EMAPTHSD17B10
SCHEMBL26632784 0.86 CSF1R (0.61) GAAALDH1A1KDM4EMAPTHSD17B10
SCHEMBL17792392 0.86 NR4A2 (0.57) GAAALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL19846945 0.83 KDM4E (0.58) GAAALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL21430761 0.82 GAA (0.55) GAAALDH1A1KDM4EMAPTRAB9A
SCHEMBL10086149 0.81 HSD17B10 (0.56) GAAALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL6643173 0.81 ALDH1A1 (0.69) GAAALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL14830757 0.80 GAA (0.58) GAAALDH1A1KDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 GAA 3839/4885ALDH1A1 3536/4885KDM4E 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.